entocort
astrazeneca pty ltd - budesonide -
entocort
astrazeneca limited - budesonide 2.25mg; ; - modified release capsule - 2.25 mg - active: budesonide 2.25mg excipient: acetyl tributyl citrate ethylcellulose gelatin methacrylic acid copolymer polysorbate 80 purified talc simeticone sugar spheres triethyl citrate
entocort ec- budesonide capsule
prometheus laboratories inc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - entocort ec is indicated for - the treatment of mild to moderate active crohn's disease involving the iluem and/or the ascending colon and - the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months. the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months. entocort ec is contraindicated in patients with known hypersensitivity to budesonide.
entocort cr 3mg capsules
lexon (uk) ltd - budesonide - modified-release capsule - 3mg
entocort cr 3 milligram capsules gastro-resistant
astrazeneca uk limited - budesonide - capsules gastro-resistant - 3 milligram
entocort® cr 3 mg gastro-resistant capsule, hard
tillotts pharma gmbh - budesonide - gastro-resistant capsule, hard - 3 milligram(s) - corticosteroids acting locally; budesonide
entocort cr 3mg capsules
tillotts pharma uk ltd - budesonide - modified-release capsule - 3mg
entocort cr 3mg capsules
waymade healthcare plc - budesonide - modified-release capsule - 3mg
entocort cr 3mg capsules
dowelhurst ltd - budesonide - modified-release capsule - 3mg
entocort cr 3mg capsules
de pharmaceuticals - budesonide - modified-release capsule - 3mg